Early anakinra treatment improves cardiac outcome of multisystem inflammatory syndrome in children, regardless of disease severity
Main finding · Persistent heart disease at end of follow-up (propensity score-adjusted)Result — go to the resultOdds ratio 0.6 95% CI 0.4–1.0Authors' conclusion
We report that early treatment with anakinra is safe and very effective in patients with severe MIS-C.
Study context
- Population
- Patients with multisystem inflammatory syndrome in children (MIS-C), treated per attending physician's decision
- Participants
- 239 patients
- Exposure
- Anakinra with or without IVIG and/or methylprednisolone vs IVIG-based initial regimens
- Outcome
- At least one of: death, failure of initial treatment (need for additional treatment for clinical worsening), cardiac involvement at end of follow-up
- Follow-up
- End
Methodological detailsmulticentre, propensity score-adjusted
- Multicentre
- Propensity score-adjusted
Main finding
As reported in the abstract
Persistent heart disease at end of follow-up (propensity score-adjusted)
Odds ratio
0.6
95% CI 0.4–1.0
Anakinra
OR 0.6 (95% CI 0.4–1.0)
Observational data: associations, not effects.
Further findings
| Outcome | Anakinra | P value |
|---|---|---|
| Persistent heart involvement at discharge (univariate analysis)Anakinra vs No initial anakinra · univariate analysis | 3/21 events | P = 0.047 |
- Persistent heart involvement at discharge (univariate analysis): No initial anakinra 66/189 events
Original publication
Early anakinra treatment improves cardiac outcome of multisystem inflammatory syndrome in children, regardless of disease severity. Rheumatology (Oxford). Published 30 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →